C5a blockade by eculizumab, a monoclonal antibody used primarily to treat paroxysmal nocturnal hematuria (PNH), showed more than encouraging results in multiple reports when used for critically ill patients suffering from COVID-19 [17,18,19]. This evidence concerns the gene C5 and paroxysmal nocturnal hemoglobinuria.